Earnings Feed
Start Free
Home/Filings/4/0001062993-23-014515
4//SEC Filing

Kummeth Charles R. 4

Accession 0001062993-23-014515

CIK 0000842023other
View on SEC.govCompany Profile

Filed

Jul 4, 8:00 PM ET

Accepted

Jul 5, 6:38 PM ET

Size

29.8 KB

Accession

0001062993-23-014515

Insider Transaction Report

Form 4
Period: 2023-06-30
BIO-TECHNE CorpTECH
Kummeth Charles R.
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2023-06-30−616,676→ 0 total
    Exercise: $26.65Exp: 2023-08-18→ Common Stock (616,676 underlying)
  • Exercise/Conversion

    Common Stock

    2023-06-30$26.65/sh+616,676$16,434,415→ 1,729,493 total
  • Tax Payment

    Common Stock

    2023-06-30$81.63/sh−390,727$31,895,045→ 1,338,766 total
Holdings

  • Common Stock

    (indirect: By Step-Daughter)
    400

  • Stock Options (Right to Buy)

    Exercise: $47.60Exp: 2026-08-07→ Common Stock (342,900 underlying)
    342,900

  • Common Stock

    (indirect: By Step-Son)
    400

  • Stock Options (Right to Buy)

    Exercise: $66.97Exp: 2027-08-05→ Common Stock (66,600 underlying)
    66,600

  • Restricted Stock Units

    → Common Stock (32,064 underlying)
    32,064

  • Stock Options (Right to Buy)

    Exercise: $94.52Exp: 2029-08-15→ Common Stock (1,200,000 underlying)
    1,200,000

  • Stock Options (Right to Buy)

    Exercise: $47.60Exp: 2026-08-07→ Common Stock (228,600 underlying)
    228,600

  • Stock Options (Right to Buy)

    Exercise: $44.33Exp: 2025-08-08→ Common Stock (361,336 underlying)
    361,336

  • Stock Options (Right to Buy)

    Exercise: $44.33Exp: 2025-08-08→ Common Stock (240,888 underlying)
    240,888

  • Restricted Stock Units

    → Common Stock (51,516 underlying)
    51,516

  • Stock Options (Right to Buy)

    Exercise: $66.97Exp: 2027-08-05→ Common Stock (299,768 underlying)
    299,768

  • Stock Options (Right to Buy)

    Exercise: $66.97Exp: 2027-08-05→ Common Stock (153,180 underlying)
    153,180

  • Stock Options (Right to Buy)

    Exercise: $31.26Exp: 2024-08-09→ Common Stock (779,084 underlying)
    779,084

  • Restricted Stock Units

    → Common Stock (52,900 underlying)
    52,900

  • Stock Options (Right to Buy)

    Exercise: $66.97Exp: 2027-08-05→ Common Stock (66,600 underlying)
    66,600

  • Stock Options (Right to Buy)

    Exercise: $120.45Exp: 2028-08-06→ Common Stock (125,260 underlying)
    125,260

  • Stock Options (Right to Buy)

    Exercise: $120.45Exp: 2028-08-06→ Common Stock (83,504 underlying)
    83,504
Footnotes (12)
  • [F1]Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024.
  • [F10]Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F11]Options to purchase 20,876 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.
  • [F12]600,000 options vest in full or in part on 7/1/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator), and 600,000 options vest in full or in part on 7/1/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F2]Fully exercisable.
  • [F3]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • [F4]17,632 shares vest on each of 8/15/2023 and 8/15/2025, and 17,636 shares vest on 8/15/2024.
  • [F5]Options to purchase 57,152 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 57,148 shares vest on each of 8/7/2022 and 8/7/2023.
  • [F6]Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F7]Options to purchase 38,292 shares vest on 8/5/21 and options to purchase 38,296 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.
  • [F8]Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
  • [F9]Options to purchase 22,200 shares vest on each of 8/5/21, 8/5/22 and 8/5/23.

Documents

1 file

Issuer

BIO-TECHNE Corp

CIK 0000842023

→
Entity typeother

Related Parties

1
  • filerCIK 0001534980

Filing Metadata

Form type
4
Filed
Jul 4, 8:00 PM ET
Accepted
Jul 5, 6:38 PM ET
Size
29.8 KB
View on SEC.gov